The role of epigenetics in the biology of multiple myeloma

Research output: Contribution to journal › Review › Research › peer-review

Standard

The role of epigenetics in the biology of multiple myeloma. / Dimopoulos, K; Gimsing, P; Grønbæk, K.

In: Blood Cancer Journal, Vol. 4, No. 5, e207, 2014, p. 1-10.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Dimopoulos, K, Gimsing, P & Grønbæk, K 2014, 'The role of epigenetics in the biology of multiple myeloma', Blood Cancer Journal, vol. 4, no. 5, e207, pp. 1-10. https://doi.org/10.1038/bcj.2014.29

APA

Dimopoulos, K., Gimsing, P., & Grønbæk, K. (2014). The role of epigenetics in the biology of multiple myeloma. Blood Cancer Journal, 4(5), 1-10. [e207]. https://doi.org/10.1038/bcj.2014.29

Vancouver

Dimopoulos K, Gimsing P, Grønbæk K. The role of epigenetics in the biology of multiple myeloma. Blood Cancer Journal. 2014;4(5):1-10. e207. https://doi.org/10.1038/bcj.2014.29

Author

Dimopoulos, K ; Gimsing, P ; Grønbæk, K. / The role of epigenetics in the biology of multiple myeloma. In: Blood Cancer Journal. 2014 ; Vol. 4, No. 5. pp. 1-10.

Bibtex

@article{df9e9013bf584028a85f9461ee380e5c,
title = "The role of epigenetics in the biology of multiple myeloma",
abstract = "Several recent studies have highlighted the biological complexity of multiple myeloma (MM) that arises as a result of several disrupted cancer pathways. Apart from the central role of genetic abnormalities, epigenetic aberrations have also been shown to be important players in the development of MM, and a lot of research during the past decades has focused on the ways DNA methylation, histone modifications and noncoding RNAs contribute to the pathobiology of MM. This has led to, apart from better understanding of the disease biology, the development of epigenetic drugs, such as histone deacetylase inhibitors that are already used in clinical trials in MM with promising results. This review will present the role of epigenetic abnormalities in MM and how these can affect specific pathways, and focus on the potential of novel 'epidrugs' as future treatment modalities for MM.",
keywords = "Animals, DNA Methylation, Epigenesis, Genetic, Epigenomics, Humans, Multiple Myeloma",
author = "K Dimopoulos and P Gimsing and K Gr{\o}nb{\ae}k",
year = "2014",
doi = "10.1038/bcj.2014.29",
language = "English",
volume = "4",
pages = "1--10",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "nature publishing group",
number = "5",

}

RIS

TY - JOUR

T1 - The role of epigenetics in the biology of multiple myeloma

AU - Dimopoulos, K

AU - Gimsing, P

AU - Grønbæk, K

PY - 2014

Y1 - 2014

N2 - Several recent studies have highlighted the biological complexity of multiple myeloma (MM) that arises as a result of several disrupted cancer pathways. Apart from the central role of genetic abnormalities, epigenetic aberrations have also been shown to be important players in the development of MM, and a lot of research during the past decades has focused on the ways DNA methylation, histone modifications and noncoding RNAs contribute to the pathobiology of MM. This has led to, apart from better understanding of the disease biology, the development of epigenetic drugs, such as histone deacetylase inhibitors that are already used in clinical trials in MM with promising results. This review will present the role of epigenetic abnormalities in MM and how these can affect specific pathways, and focus on the potential of novel 'epidrugs' as future treatment modalities for MM.

AB - Several recent studies have highlighted the biological complexity of multiple myeloma (MM) that arises as a result of several disrupted cancer pathways. Apart from the central role of genetic abnormalities, epigenetic aberrations have also been shown to be important players in the development of MM, and a lot of research during the past decades has focused on the ways DNA methylation, histone modifications and noncoding RNAs contribute to the pathobiology of MM. This has led to, apart from better understanding of the disease biology, the development of epigenetic drugs, such as histone deacetylase inhibitors that are already used in clinical trials in MM with promising results. This review will present the role of epigenetic abnormalities in MM and how these can affect specific pathways, and focus on the potential of novel 'epidrugs' as future treatment modalities for MM.

KW - Animals

KW - DNA Methylation

KW - Epigenesis, Genetic

KW - Epigenomics

KW - Humans

KW - Multiple Myeloma

U2 - 10.1038/bcj.2014.29

DO - 10.1038/bcj.2014.29

M3 - Review

C2 - 24786391

VL - 4

SP - 1

EP - 10

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 5

M1 - e207

ER -

ID: 138425148